文献速递神经核医学

[18F]FP-CIT靶向多巴胺转运体用于帕金森病诊断的临床前评估:药代动力学与疗效分析

Preclinical evaluation of [18F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson's disease: pharmacokinetic and efficacy analysis.
PubMed 文献 · EJNMMI Res · 2024-07-03

本研究在小鼠和大鼠6-OHDA帕金森病模型中评估[18F]FP-CIT的药代动力学与诊断效能,显示注射后1分钟纹状体摄取达23.50±12.46%ID/g,60分钟内快速清除,主要代谢器官为肠道、肝脏和肾脏;动物PET/CT与酪氨酸羟化酶免疫组化高度相关(绝对值R=0.803,p=0.0017;比值R=0.973,p=0.0011)。

要点

  • [18F]FP-CIT注射后1分钟纹状体摄取最高达23.50±12.46%ID/g,60分钟内快速排泄。
  • 主要代谢器官为肠道、肝脏和肾脏,6小时内21.46±9.53%的化合物被排泄。
  • 帕金森病模型中[18F]FP-CIT PET与免疫组化高度相关(绝对值R=0.803,p=0.0017;比值R=0.973,p=0.0011)。

核心结论

  • 本研究填补了[18F]FP-CIT临床前研究不足的空白,包括其ADME、代谢产物和效能。
  • 药理学结果包括准确诊断、快速循环和[18F]FP-CIT排泄,提供补充证据表明[18F]FP-CIT可在临床安全有效地诊断帕金森病,尽管它已在临床上使用。

研究设计与样本

  • 在小鼠中进行生物分布、代谢物和排泄分析,并使用6-羟基多巴胺(6-OHDA)在大鼠中诱导帕金森病模型。
  • 通过动物PET/CT成像评估[18F]FP-CIT对多巴胺受体的靶向效率,并与靶向酪氨酸羟化酶的免疫组化(IHC)进行相关性分析。

主要发现

  • [18F]FP-CIT注射后快速循环,注射后1分钟纹状体摄取最高达23.50±12.46%ID/g,60分钟内快速排泄。
  • 主要代谢器官为肠道、肝脏和肾脏;肠道摄取约5%ID/g;肝脏摄取逐渐增加,60分钟后达最大值并开始排泄;肾脏在10分钟后快速消除。
  • 排泄研究中6小时内21.46±9.53%的化合物被排泄,证实快速消除。
  • 在帕金森病模型中,[18F]FP-CIT PET与IHC高度相关:绝对值R=0.803,p=0.0017;比值R=0.973,p=0.0011。

临床怎么用

  • 作者认为[18F]FP-CIT的药理学结果(包括准确诊断、快速循环和排泄)提供补充证据,表明其可在临床安全有效地诊断帕金森病,尽管它已在临床上使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (FP-CIT), the representative cocaine derivative used in dopamine transporter imaging, is a promising biomarker, as it reflects the severity of Parkinson's disease (PD). 123I- and 18F-labeled FP-CIT has been used for PD diagnosis. However, preclinical studies evaluating [18F]FP-CIT as a potential diagnostic biomarker are scarce. Among translational research advancements from bench to bedside, translating preclinical findings into clinical practice is one-directional. The aim of this study is to employ a circular approach, beginning back from the preclinical stage, progressing to the supplementation of [18F]FP-CIT, and subsequently returning to clinical application. We investigated the pharmacokinetic properties of [18F]FP-CIT and its efficacy for PD diagnosis using murine models. RESULTS: Biodistribution, metabolite and excretion analyses were performed in mice and PD models were induced in rats using 6-hydroxydopamine (6-OHDA). The targeting efficiency of [18F]FP-CIT for the dopamine receptor was assessed through animal PET/CT imaging. Subsequently, correlation analysis was conducted between animal PET/CT imaging results and immunohistochemistry (IHC) targeting tyrosine hydroxylase. Rapid circulation was confirmed after [18F]FP-CIT injection. [18F]FP-CIT reached the highest uptake of 23.50 ± 12.46%ID/g in the striatum 1 min after injection, and it was rapidly excreted within 60 min. The major metabolic organs of [18F]FP-CIT were confirmed to be the intestines, liver, and kidneys. Its uptake in the intestine was approximately 5% ID/g. The uptake in the liver gradually increased, with excretion beginning after reaching a maximum after 60 min. The kidneys exhibited rapid elimination after 10 min. In the excretion study, rapid elimination was verified, with 21.46 ± 9.53% of the compound excreted within a 6 h period. Additionally, the efficacy of [18F]FP-CIT PET was demonstrated in the PD model, with a high correlation with IHC for both the absolute value (R = 0.803, p = 0.0017) and the ratio value (R = 0.973, p = 0.0011). CONCLUSIONS: This study fills the gap regarding insufficient preclinical studies on [18F]FP-CIT, including its ADME, metabolites, and efficiency. The pharmacological results, including accurate diagnosis, rapid circulation, and [18F]FP-CIT excretion, provide complementary evidence that [18F]FP-CIT can be used safely and efficiently to diagnose PD in clinics, although it is already used in clinics.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ahn JH, Kim MH, Lee K, et al. Preclinical evaluation of [18F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson's disease: pharmacokinetic and efficacy analysis. EJNMMI Res. 2024. PMID: 38958796. doi:10.1186/s13550-024-01121-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。